|
US7309760B2
(en)
*
|
2001-04-17 |
2007-12-18 |
The Board Of Trustees Of The University Of Arkansas |
Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
|
|
CA2443617C
(en)
|
2001-04-17 |
2013-12-10 |
The Board Of Trustees Of The University Of Arkansas |
Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
|
|
DK2891666T3
(en)
*
|
2002-10-16 |
2017-10-02 |
Purdue Pharma Lp |
Antibodies that bind cell-associated CA 125 / O722P and methods for its use
|
|
MXPA05005237A
(es)
*
|
2002-11-15 |
2005-08-16 |
Univ Arkansas |
Gen ca125 y su uso para diagnostico e intervenciones terapeuticas.
|
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
|
RU2404810C9
(ru)
|
2004-06-01 |
2015-06-20 |
Дженентек, Инк. |
Конъюгаты антитело-лекарственное средство и способы
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
CN104447992A
(zh)
|
2004-09-23 |
2015-03-25 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
JP4987698B2
(ja)
|
2005-03-31 |
2012-07-25 |
中外製薬株式会社 |
癌関連抗原アナログペプチド、およびその利用
|
|
AU2007211085A1
(en)
*
|
2006-01-27 |
2007-08-09 |
Tripath Imaging, Inc. |
Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
|
|
US8097242B2
(en)
*
|
2006-10-05 |
2012-01-17 |
The Board Of Trustees Of The University Of Arkansas |
Target CA125 peptides for cancer immunotherapy
|
|
JP5469600B2
(ja)
|
2007-07-16 |
2014-04-16 |
ジェネンテック， インコーポレイテッド |
抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
|
|
EP2176295B1
(en)
|
2007-07-16 |
2014-11-19 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
US8546137B2
(en)
|
2007-09-27 |
2013-10-01 |
The Board Of Trustees Of The University Of Arkansas |
Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
AU2010292172A1
(en)
|
2009-09-09 |
2012-05-03 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
AU2011239507B2
(en)
|
2010-04-15 |
2015-04-09 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
KR101839163B1
(ko)
|
2010-06-08 |
2018-03-15 |
제넨테크, 인크. |
시스테인 조작된 항체 및 접합체
|
|
CN103313990B
(zh)
|
2010-11-17 |
2016-07-20 |
基因泰克公司 |
丙氨酰美登醇抗体偶联物
|
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
US11135303B2
(en)
|
2011-10-14 |
2021-10-05 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
|
HRP20180945T1
(hr)
|
2012-10-12 |
2018-08-10 |
Adc Therapeutics Sa |
Konjugati protutijelo-pirolobenzodiazepin
|
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
HUE042731T2
(hu)
|
2012-10-12 |
2019-07-29 |
Adc Therapeutics Sa |
Pirrolobenzodiazepin-antitest konjugátumok
|
|
AU2013328580B2
(en)
|
2012-10-12 |
2016-01-21 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP6270859B2
(ja)
|
2012-10-12 |
2018-01-31 |
エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ |
ピロロベンゾジアゼピン−抗体結合体
|
|
AU2013328628B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
|
|
JP6527466B2
(ja)
|
2012-12-21 |
2019-06-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体
|
|
EP2935268B2
(en)
|
2012-12-21 |
2021-02-17 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
MX364330B
(es)
|
2013-03-13 |
2019-04-23 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
AR096287A1
(es)
|
2013-03-13 |
2015-12-23 |
Spirogen Sàrl |
Pirrolobenzodiacepinas y conjugados
|
|
CN105209077B
(zh)
|
2013-03-13 |
2019-06-11 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓以及其结合物
|
|
MX2016001862A
(es)
|
2013-08-12 |
2016-08-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN105873614B
(zh)
|
2013-12-16 |
2020-10-30 |
基因泰克公司 |
肽模拟化合物及其抗体-药物缀合物
|
|
BR112016013258A2
(pt)
|
2013-12-16 |
2018-01-16 |
Genentech Inc |
composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
|
|
BR112016013861A2
(pt)
|
2013-12-16 |
2017-10-10 |
Genentech Inc |
conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
|
EP3191134B1
(en)
|
2014-09-12 |
2019-11-20 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
|
EP3235820A1
(en)
|
2014-09-17 |
2017-10-25 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
|
EP3262071B8
(en)
|
2014-09-23 |
2022-05-18 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
|
US10780096B2
(en)
|
2014-11-25 |
2020-09-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
JP6752204B2
(ja)
|
2014-12-03 |
2020-09-09 |
ジェネンテック， インコーポレイテッド |
四級アミン化合物及びその抗体−薬物コンジュゲート
|
|
WO2016149368A1
(en)
*
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
|
IL260877B2
(en)
*
|
2015-03-27 |
2023-10-01 |
Immatics Biotechnologies Gmbh |
New peptides and a combination of peptides for use in immunotherapy against different types of tumors
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201507030D0
(en)
*
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック， インコーポレイテッド |
Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
|
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
|
EP3482205A1
(en)
|
2016-07-08 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
|
EP3496763A1
(en)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
HRP20231281T1
(hr)
*
|
2016-09-23 |
2024-02-02 |
Regeneron Pharmaceuticals, Inc. |
Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom
|
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
KR102687092B1
(ko)
*
|
2016-10-27 |
2024-07-22 |
엘지디스플레이 주식회사 |
표시장치 및 그 제조방법
|
|
EP3544636B1
(en)
|
2017-02-08 |
2021-03-31 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CA3059519C
(en)
|
2017-04-18 |
2021-03-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
CN110536703B
(zh)
|
2017-04-20 |
2024-07-12 |
Adc治疗有限公司 |
使用抗axl抗体-药物缀合物的组合疗法
|
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
|
MX384245B
(es)
|
2017-08-18 |
2025-03-14 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina
|
|
SG11202001907QA
(en)
|
2017-09-20 |
2020-04-29 |
Ph Pharma Co Ltd |
Thailanstatin analogs
|
|
AU2018383662C1
(en)
*
|
2017-12-13 |
2023-02-09 |
Inovio Pharmaceuticals, Inc. |
Cancer vaccines targeting MUC16 and uses thereof
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
AU2020242747B2
(en)
|
2019-03-15 |
2025-09-18 |
Medimmune Limited |
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
AU2021362997A1
(en)
|
2021-11-03 |
2024-05-16 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
EP4637833A2
(en)
|
2022-12-23 |
2025-10-29 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
|
CN121263210A
(zh)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
|
|
WO2025101837A1
(en)
*
|
2023-11-10 |
2025-05-15 |
Eccletech Llc |
Biological devices and methods of using the same for detection of different types of cancer
|